1. Strengthening regional commitment to ensuring access to medical abortion medicines in WHO's South-East Asia region: report of a participatory assessment and workshop.
- Author
-
Upadhyay, Meera Thapa, Fusire, Terence, Loi, Ulrika Rehnström, Sorhaindo, Annik, Salahuddin, Mohammed, Hossain, Mohammed Ayub, Tshomo, Tashi, Mulati, Erna, Daisy, Lovely, Anggraweni, Dian Putri, Gultom, Tumiur, Indrawati, Fitri, Jenyfa, Mariyam, Than, Myint Myint, Bhattarai, Bharat, Moonasinghe, Loshan, Mathota, Chaminda, Jitruknatee, Anchalee, Cham, Celeste, and Ganatra, Bela
- Subjects
HEALTH services accessibility ,MEDICAL protocols ,COMBINATION drug therapy ,PATIENT safety ,REPRODUCTIVE health ,RESEARCH funding ,ADULT education workshops ,MISOPROSTOL ,MIFEPRISTONE ,SEXUAL health - Abstract
Background: In 2019, the World Health Organization identified improving access to safe abortion as an important priority toward improving sexual and reproductive health and rights and achieving Sustainable Development Goals. One strategy for addressing this priority is strengthening access to medicines for medical abortion. All 11 countries in the South-East Asia Region have some indications for legal abortion and permit post-abortion care. Therefore, strengthening access to medical abortion medicines is a reasonable strategy for improving access to safe abortion for the Region. Methodology: We applied an adapted version of an existing World Health Organization landscape assessment protocol for the availability of medical abortion medicines at the country-level in the South-East Asia Region. We collected publicly available data on the existence of national health laws, policies, and standard treatment guidelines; inclusion of medical abortion medicines in the national essential medicines list; and marketing authorization status for medical abortion medicines for each country and verified by Ministries of health. The findings were once more presented, discussed and recommendations were formulated during regional technical consultation workshop. Each country teams participated in the process, and subsequently, the suggestions were validated by representatives from Ministries of Health.. Results: Few countries in the Region currently have national policies and guidelines for comprehensive safe abortion. However, either mifepristone-misoprostol in combination or misoprostol alone (for other indications) is included in national essential medicines lists in all countries except Indonesia and Sri Lanka. Few countries earmark specific public funds for procuring and distributing medical abortion commodities. In countries where abortion is legal, the private sector and NGOs support access to medical abortion information and medicines. Several countries only allow registered medical practitioners or specialists to administer medical abortion. Conclusion: Following this rapid participatory assessment and technical consultation workshop, the World Health Organization South-East Asia Regional Technical Advisory and Sexual and Reproductive Health and Rights technical committee recommended priority actions for policy and advocacy, service delivery, and monitoring and evaluation, and indicated areas for support. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF